Cardiovascular Drug Discovery Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is cardiovascular drug discovery market size?

USD 1,285.8 million in 2026 and USD 2,934.1 million by 2036 at an 8.6% CAGR.

Sales for cardiovascular drug discovery is projected to expand at 8.6% CAGR between 2026 and 2036, increasing valuation from USD 1,285.8 million in 2026 to USD 2,934.1 million by 2036. Pharmaceutical scientists actively prioritize drug mechanisms driven by human genetics and measurable disease biology. This targeted research strategy is essential to address the growing global burden of cardiovascular illness. A World Health Organization update issued in September 2025 estimated 1.4 billion adults living with hypertension during 2024. Resulting with immense disease exposure directly sustaining ongoing research into specialized therapies designed for heterogeneous vascular and cardiometabolic patient populations.

Diverse international research sponsors apply distinct regional criteria on evaluating cardiovascular drug portfolios. Research sponsors in the United States and Germany emphasize regulatory evidence and translational records during portfolio reviews. Developers in the United Kingdom and South Korea favor genomic cohorts and shorter clinical-study initiation periods. Extensive genetic databases provide the essential scientific foundation to support such genomic development strategies. The UK Biobank confirmed whole-genome sequencing data for 500,000 participants in June 2025. Leading this greater cohort depth directly to improve target qualification across heart failure and vascular disease subtypes.

Summary of Cardiovascular Drug Discovery Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Cardiovascular discovery advances as sponsors connect causal disease biology with measurable clinical objectives. Program decisions reflect human genetics and translational testing across specialist research teams. Research teams seek validated targets associated with heart failure and vascular disease mechanisms. Pharmaceutical sponsors compare phenotype assays with genomic evidence during candidate selection. Biomarker planning improves patient stratification during early clinical development. Academic collaborations provide disease models and longitudinal cardiovascular datasets. Regulatory engagement improves evidence planning across advanced research programs.
Product and Segment View	Segment direction is led by discovery followed by target identification & validation and heart failure. Program review is expected to concentrate on causal evidence and development readiness across cardiovascular portfolios. Discovery is estimated to garner 53.7% share in 2026, aided by extensive activity across target research and candidate selection. Target identification & validation is predicted to represent 42.1% share in 2026, reflected by sponsor emphasis on mechanism confidence and early attrition control. Heart Failure is anticipated to secure 36.0% share in 2026, influenced by heterogeneous disease mechanisms and continuing therapeutic gaps.
Geography and Growth Outlook	Country movement differs through research infrastructure and clinical-study capacity across participating pharmaceutical centers. Sponsor progress reflects cohort access and specialist cardiovascular expertise. United Kingdom is likely to expand at 10.7% CAGR by 2036, led by genomic resources and clinical-study reform. Germany is set to rise at 9.2% CAGR during the forecast period, guided by university cardiology networks and pharmaceutical research capacity. South Korea is expected to increase at 8.8% CAGR between 2026 and 2036, backed by biotechnology clusters and tertiary-hospital research programs.
Competitive View	Competition centers on target quality and cardiovascular specialization across pharmaceutical and biotechnology pipelines. Commercial progress favors companies maintaining scientific depth from early discovery into clinical development. Pfizer Inc. and AstraZeneca PLC are expected to receive consideration led by established cardiovascular research operations. Novartis AG and Bayer AG are projected to compete based on cardiovascular pipelines and disease-specific scientific programs. Cardurion Pharmaceuticals and Tenaya Therapeutics are anticipated to attract specialist review due to focused cardiovascular mechanisms and genetic-medicine research.
Analyst Perspective	Cardiovascular drug discovery requires causal evidence and disease-specific endpoints suited to development decisions. Program quality is expected to improve depending on stronger connections between experimental biology and clinical phenotype data. Research teams assess target evidence led by human genetics and functional disease models. Sponsors examine biomarker feasibility during candidate-selection decisions across cardiovascular programs. Clinical planning benefits from early engagement with specialist investigators and regulatory teams. - Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights

Source: Future Market Insights analysis, 2026.

How is cardiovascular drug discovery market segmented?

The cardiovascular drug discovery industry is segmented by approach, therapeutic focus, drug type, stage, and region.

The cardiovascular drug discovery market is segmented by approach, therapeutic focus, drug type, stage, and region. Approach coverage includes Target Identification & Validation and High-Throughput Screening followed by AI/ML-Driven Discovery and Phenotypic Screening. Therapeutic Focus coverage includes Heart Failure and Atherosclerotic Cardiovascular Disease followed by Arrhythmias and Cardiomyopathies and Hypertension. Drug Type coverage encompasses Small Molecules and Biologics supported by RNA Therapeutics and Gene Therapy. Stage coverage spans Discovery and Preclinical programs followed by Clinical development. Regional coverage includes North America and Latin America together with Western Europe and Eastern Europe. East Asia and South Asia and Pacific precede Middle East and Africa within geographic assessment.

Why does Target Identification & Validation shape approach selection?

Research teams sequence validation assays according to genetic strength and reproducible findings from disease-specific functional models. Chemistry investment begins with clearer selection criteria for tractable mechanisms carrying measurable cardiovascular effects across validated assays. Minikel and colleagues reported a 2.6 times greater probability of clinical success for drug mechanisms carrying human genetic evidence in April 2024. Such evidence improves early screening of cardiovascular targets and directs experimental resources toward mechanisms supported by causal disease biology.

• Based on approach, target identification & validation is estimated to represent 42.1% share in 2026 owing to sponsor emphasis on mechanism confidence prior to extensive chemistry investment. Human genetics and disease-tissue studies improve qualification of cardiovascular pathways requiring measurable biological support.
• High-throughput screening examines compound activity across defined assay systems and selected molecular targets. AI-enabled drug discovery and phenotypic screening extend candidate review through computational ranking and functional cellular responses.

Why does Heart Failure shape therapeutic-focus demand?

Heart Failure Society of America estimated 6.7 million Americans aged above 20 years living with heart failure in September 2024. Patient heterogeneity sustains research across myocardial function and inflammatory signaling and cardiac-remodeling mechanisms. Distinct phenotypes require separate experimental models for contractile dysfunction and electrical instability during candidate screening. Endpoint planning benefits from early separation of patient groups carrying different biological pathways and response patterns.

• In 2026, heart failure is anticipated to secure 36.0% share in 2026 due to continuing therapeutic gaps across preserved and reduced ejection-fraction populations. Personalized medicine assists phenotype-based research for patient groups presenting different disease mechanisms and clinical responses.
• Atherosclerotic cardiovascular disease and hypertension support discovery programs examining vascular inflammation and lipid regulation. Arrhythmias and cardiomyopathies require specialist research into ion channels and inherited cardiac mechanisms across defined patient cohorts.

Why do Small Molecules shape drug-type selection?

Researchers compare intracellular target access against exposure profiles during initial modality selection. Manufacturing feasibility receives a separate assessment during entry into resource-intensive candidate optimization and formulation studies. United States Food and Drug Administration recorded 50 novel drug approvals during 2024 in a January 2025 review. Established chemistry and regulatory pathways preserve interest in small-molecule candidates across cardiovascular target programs.

• Small molecules are predicted to secure 31.0% share of drug-type in 2026, backed by oral-delivery potential and established medicinal-chemistry processes. Drug designing tools assist potency assessment and candidate optimization across enzyme and receptor targets.
• Biologics and RNA therapeutics provide modality options for extracellular proteins and genetically defined mechanisms. Gene therapy supports inherited cardiovascular programs requiring durable biological correction and specialist development capabilities.

Why does Discovery shape stage selection?

European Medicines Agency recorded 121 initial evaluation applications during 2024 in its annual report published in June 2025. Early portfolio quality influences candidate progression from discovery activity into formal regulatory review. Program teams define evidence thresholds for every transition using pharmacology and safety findings. Development resources concentrate on candidates meeting predefined requirements for exposure and biological response.

• By stage, discovery is forecast to account for 53.7% share in 2026 as it reflects extensive target research and lead-optimization activity. Drug discovery informatics assists evidence assessment across chemistry and biological datasets during candidate-ranking decisions.
• Preclinical programs assess pharmacological activity and safety across laboratory models prior to human evaluation. Clinical development combines dose assessment and therapeutic evidence across patients selected through biomarker and phenotype criteria.

What are drivers, restraints, and opportunities in cardiovascular drug discovery market?

Genetic evidence and disease-specific research platforms support cardiovascular target evaluation. Biological uncertainty and development expense may delay candidate progression across successive research stages.

• Driver: Research sponsors need stronger causal evidence for selecting cardiovascular targets with measurable therapeutic potential. Human genetics and functional disease models improve confidence during portfolio review and candidate advancement.
• Restraint: Complex cardiovascular biology creates attrition exposure across preclinical and clinical programs. Inadequate biomarkers may weaken patient selection and delay interpretation of therapeutic response.
• Opportunity: Population-scale datasets create additional pathways for identifying inherited cardiovascular mechanisms and disease subtypes. Computational analysis improves target ranking across clinical and genomic information.

Population-scale datasets strengthen mechanism selection across cardiovascular subgroups. All of Us Research Program expanded research data to more than 633,000 participants in February 2025. Clinical Next-Generation Sequencing Data Analysis supports interpretation of inherited risk across underrepresented ancestry groups. Research sponsors compare variant frequency against longitudinal phenotype records during selection of disease mechanisms for experimental validation. Cohort diversity improves confidence in targets intended for patient groups carrying different inherited risks.

Development expense constrains progression from candidate selection into clinical testing. Nature Reviews Drug Discovery reported an estimated USD 880 million cost for bringing a new medicine to approval in August 2024. Financial exposure encourages stricter evidence thresholds during cardiovascular portfolio decisions. Sponsors allocate later-stage resources to candidates carrying defensible biomarkers and measurable pharmacological responses. Early termination protects research budgets from prolonged testing of weakly differentiated mechanisms.

New genetic variants create pathways for cardiovascular target discovery and patient stratification. National Institutes of Health identified more than 275 million previously unreported genetic variants in February 2024. Bioinformatics analysis helps researchers compare inherited signals against cardiovascular phenotype records. Functional studies then test selected variants for changes in disease pathways under controlled conditions. Evidence from laboratory models supports prioritization of mechanisms carrying measurable biological effects.

How are country CAGRs aligned in cardiovascular drug discovery market?

Country	CAGR
United Kingdom	10.7%
Germany	9.2%
South Korea	8.8%
United States	8.1%
Japan	7.1%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in cardiovascular drug discovery market?

The country comparison shows a gradual step-down in growth across the markets covered. The United Kingdom sits at the upper end of the range. Germany and South Korea form a closely grouped second tier. The United States follows with slightly lower growth. Japan remains at the lower end of the comparison. The 3.6-point spread shows these markets sharing a strong growth outlook, even with their relative positions indicating different levels of market momentum.

• The United Kingdom leads the comparison and establishes Western Europe as the notable growth cluster among the markets shown.
• Germany and South Korea follow closely, indicating for neither market falling far behind the leading country.
• The United States forms the next growth band and maintains a relatively small gap from the middle tier.
• Japan records the slowest growth among the listed markets, yet its forecast remains strong within the wider market context.
• The pattern resembles a gradual downward slope rather than a sharp separation between high-growth and low-growth markets.

Markets with broadly similar CAGRs can still present different entry conditions due to research infrastructure and clinical-development readiness. The full report provides country-level analysis across North America, Latin America, Europe, East Asia, South Asia and Pacific and the Middle East and Africa.

Country-wise Analysis

• Cardiovascular drug discovery sales in the United Kingdom are predicted to scale at 10.7% CAGR between 2026 and 2036, backed by genomic cohorts and clinical-research reform. Coordinated academic networks improve transition from target evidence into patient studies. Department for Science, Innovation and Technology set a commercial trial-setup target below 150 days by March 2026 in its July 2025 sector plan. National cohort resources help sponsors match inherited risk profiles with clinical cardiovascular records. Shared research infrastructure reduces duplicated work during biomarker development among participating academic centers.
• Research centers in Germany combine medicinal chemistry expertise with university cardiology programs serving complex cardiovascular studies. German Federal Statistical Office recorded residents aged at least 65 years at 23.2% of national population during 2024 in its November 2025 update. University hospitals provide concentrated access to investigators experienced in heart failure and vascular disorders. Pharmaceutical developers benefit from established medicinal-chemistry teams located near specialist clinical institutions. Demand in Germany is projected to rise at 9.2% CAGR during the study period, aided by specialist trial capacity and established regulatory processes.
• Biotechnology clusters and tertiary hospitals provide sponsors in South Korea with concentrated research and clinical capabilities. Cardiovascular drug discovery sector in South Korea is anticipated to progress at 8.8% CAGR between 2026 and 2036, reflecting rapid evaluation of genetic and cardiometabolic programs. Ministry of Data and Statistics recorded residents aged at least 65 years at 19.2% of national population during 2024 in March 2025. Hospital-centered research networks support efficient recruitment for biomarker-defined cardiovascular studies. Domestic biotechnology groups contribute specialized platform knowledge for genetic and small-molecule programs.
• Academic medical centers provide sponsors with specialist investigators and diverse cardiovascular patient populations. United States Food and Drug Administration recorded first-cycle approval for 37 of 50 novel medicines during 2024 in January 2025. Large research networks provide access to disease-specific cohorts for protocol development. Experienced regulatory teams support evidence planning across discovery and clinical portfolio decisions. Industry in the United States is estimated to expand at 8.1% CAGR during the assessment period, guided by established biotechnology and clinical-development networks.
• The market in Japan is expected top grow at 7.1% CAGR from 2026 to 2036, influenced by specialist pharmaceutical research and measured portfolio review. Academic institutions offer structured settings for cardiovascular pharmacology and biomarker studies. Statistics Bureau of Japan recorded 36.243 million residents aged at least 65 years during 2024 in its April 2025 publication. Older patient cohorts provide extensive clinical context for heart failure and vascular research. Domestic pharmaceutical expertise supports careful dose selection and safety planning for age-associated conditions.

Who are notable companies in cardiovascular drug discovery market?

Pfizer Inc., Novartis AG, AstraZeneca PLC, Bayer AG, Bristol Myers Squibb, Amgen Inc., Eli Lilly and Company, Cardurion Pharmaceuticals, and Tenaya Therapeutics are the key companies shaping this market.

Competition in cardiovascular drug discovery is anticipated to center on target quality and disease specialization. Research teams are likely to compare companies due to translational models and clinical-development experience. Multinational companies are expected to compete through portfolio depth and established trial operations. Focused biotechnology developers are projected to receive attention driven by mechanistic concentration and specialist cardiovascular teams.

• Pfizer Inc. and AstraZeneca PLC are expected to receive consideration led by established cardiovascular and internal-medicine pipelines. Research teams are likely to compare disease coverage and translational evidence during portfolio assessment.
• Novartis AG and Bayer AG are projected to compete based on cardiovascular pipelines and specialist clinical-development capabilities. External research collaborations expand access to target-identification platforms and cardiovascular disease models.
• Bristol Myers Squibb and Eli Lilly and Company are anticipated to support competition depending on extensive pharmaceutical research operations. Portfolio decisions are expected to reflect mechanism differentiation and clinical evidence across defined cardiovascular indications.
• Cardurion Pharmaceuticals and Tenaya Therapeutics are forecast to receive specialist review depending on focused cardiovascular science. Company assessment is likely to examine signaling pathways and genetic-medicine programs directed toward heart disease.

Competitive Benchmarking: Cardiovascular Drug Discovery Market

Company	Portfolio Depth	Cardiovascular Match	Research Support	Service Reach
Pfizer Inc.	High	High	High	Global
Novartis AG	High	High	High	Global
AstraZeneca PLC	High	High	High	Global
Bayer AG	High	High	High	Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Cardiovascular Drug Discovery Market

• In February 2025, Novartis announced an agreement to acquire Anthos Therapeutics and return abelacimab to its cardiovascular pipeline. Company information placed abelacimab in Phase 3 development for preventing stroke and systemic embolism among patients with atrial fibrillation.
• Bayer and Broad Institute extended a cardiovascular research collaboration for five years in June 2025. Expanded work centers on precision-cardiology target identification and human cardiomyocyte validation for new therapeutic approaches.
• In August 2025, Cardurion Pharmaceuticals completed enrollment across two global CYCLE studies evaluating CRD-750 in chronic heart failure. Completed Phase 2 enrollment advanced PDE9 inhibitor assessment across reduced and preserved ejection-fraction populations.

Key Players in Cardiovascular Drug Discovery Market

Established pharmaceutical companies

• Pfizer Inc.
• Novartis AG
• AstraZeneca PLC
• Bristol Myers Squibb
• Bayer AG
• Amgen Inc.
• Eli Lilly and Company

Focused cardiovascular developers

• Cardurion Pharmaceuticals
• Tenaya Therapeutics

Cardiovascular Drug Discovery Market Report Scope

Coverage Field	Report Scope
Market Breakdown	Cardiovascular Drug Discovery Market breakdown by approach, therapeutic focus, drug type, stage, and region
Quantitative Units	USD million in 2026 to USD million by 2036 at CAGR
Market Definition	Cardiovascular drug discovery includes research products and services supporting target selection and candidate development across cardiovascular disorders.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa
Countries Covered	United Kingdom, Germany, South Korea, United States, and Japan
Key Companies Profiled	Pfizer Inc., Novartis AG, AstraZeneca PLC, Bristol Myers Squibb, Bayer AG, Amgen Inc., Eli Lilly and Company, Cardurion Pharmaceuticals, and Tenaya Therapeutics
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology using segment shares and country CAGRs with research activity and company participation and therapeutic evidence

Source: Future Market Insights analysis, 2026.

Cardiovascular Drug Discovery Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: Future Market Insights analysis, 2026.

Cardiovascular Drug Discovery Market by Segments

Cardiovascular Drug Discovery Market segmented by Approach:

• Target Identification & Validation
• High-Throughput Screening
• AI/ML-Driven Discovery
• Phenotypic Screening

Cardiovascular Drug Discovery Market segmented by Therapeutic Focus:

• Heart Failure
• Atherosclerotic Cardiovascular Disease
• Arrhythmias
• Cardiomyopathies
• Hypertension

Cardiovascular Drug Discovery Market segmented by Drug Type:

• Small Molecules
• Biologics
• RNA Therapeutics
• Gene Therapy

Cardiovascular Drug Discovery Market segmented by Stage:

• Discovery
• Preclinical
• Clinical

Cardiovascular Drug Discovery Market segmented by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• All of Us Research Program. (2025, February 24). All of Us adds data from 50% more participants in largest data expansion to date.
• Bayer AG. (2025, June 11). Bayer and Broad Institute extend research collaboration to develop new cardiovascular therapies.
• Cardurion Pharmaceuticals, Inc. (2025, August 6). Cardurion Pharmaceuticals completes enrollment in Phase 2 CYCLE trials evaluating CRD-750, a novel PDE9 inhibitor, in heart failure.
• Department for Business and Trade, Department of Health and Social Care, Department for Science, Innovation and Technology, and Office for Life Sciences. (2025, July 16). Life Sciences Sector Plan.
• European Medicines Agency. (2025, June 10). 2024 annual report of the European Medicines Agency.
• German Federal Statistical Office. (2025, November 19). Basic indicators: Germany.
• Heart Failure Society of America. (2024, September 24). Cardiology experts warn of rising heart failure rates and worsening disparities in new 2024 report.
• Minikel, E. V., Painter, J. L., Dong, C. C., & Nelson, M. R. (2024, April 17). Refining the impact of genetic evidence on clinical success. Nature, 629, 624-629.
• Ministry of Data and Statistics. (2025, March 25). Social indicators in 2024.
• Mullard, A. (2024, August 5). Per-patient approach to calculating drug development costs yields lower estimate. Nature Reviews Drug Discovery, 23, 650.
• National Institutes of Health. (2024, February 19). 275 million new genetic variants identified in NIH precision medicine data.
• Novartis AG. (2025, February 11). Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront.
• Statistics Bureau of Japan. (2025, April 14). Current population estimates as of October 1, 2024.
• UK Biobank. (2025, June 17). Whole genome sequencing data.
• United States Food and Drug Administration. (2025, January 8). CDER brings many safe and effective therapies to patients and consumers in 2024.
• World Health Organization. (2025, September 25). Hypertension.

This bibliography is provided for reader reference and is not exhaustive. The full report contains a complete reference list and detailed citations.

This Report Answers

• • What segments influence demand across approach and therapeutic focus with drug type and stage?
  • How do research teams evaluate targets prior to candidate advancement across cardiovascular programs?
  • How do country growth rates differ across profiled research and development environments?
  • What companies compete through portfolio depth and cardiovascular specialization and research support?
  • How are forecasts validated through bottom-up and top-down analysis using independent indicators?
  • What evidence do sponsors assess prior to cardiovascular portfolio advancement and clinical development?
  • How do genetic evidence and disease models influence target selection across research programs?
  • What limits returns for sponsors investing in cardiovascular drug discovery programs?
  • How do biomarker plans and patient stratification influence cardiovascular clinical development?
  • What company capabilities improve long-term confidence across cardiovascular research programs?